#United States #oncology #Pleasanton #10x Genomics #Fred Hutch

10x Genomics Partners with Fred Hutch for Groundbreaking Cancer Solutions

In a significant move that promises to transform cancer research and treatment, 10x Genomics, a pioneering force in life science technology, has announced a collaborative effort with the Fred Hutchinson Cancer Center, a premier institution renowned for its cancer research. This partnership aims to advance the understanding and treatment of both solid tumors and hematologic malignancies by leveraging cutting-edge single cell and spatial biology technologies.

The collaboration marks a major milestone for 10x Genomics as it expands its clinical research initiatives beyond the realm of solid tumors to include blood cancers. This strategic move is designed to capitalize on the potential of single cell analysis and spatial technologies for refining oncology diagnostics, ultimately leading to better patient outcomes.

Focusing on Bladder Cancer and Acute Myeloid Leukemia

The researchers from 10x Genomics and Fred Hutch will embark on a series of multifaceted projects. The first project will employ 10x’s advanced Flex Apex and Xenium platforms to analyze tumor samples from patients suffering from advanced bladder cancer. These patients will have undergone various treatments, including antibody-drug conjugates and immune checkpoint inhibitors. The objective is to discern relationships between drug target expression, tumor microenvironment characteristics, and how these factors influence treatment responses and clinical outcomes.

By identifying specific biomarkers linked to treatment efficacy, researchers hope to aid oncologists in making more informed decisions regarding therapy selection for their patients. This ambitious approach underscores the importance of personalized medicine in oncology, allowing for tailored treatment plans that consider the unique genetic makeup of each patient’s cancer.

In conjunction with the bladder cancer study, the second project will focus on residual disease detection in acute myeloid leukemia (AML). For AML patients, monitoring the presence of leukemic cells post-treatment is crucial for effective management and ongoing care. 10x Genomics and Fred Hutch aim to enhance existing methodologies by utilizing single cell analysis to improve the detection and characterization of residual disease, moving beyond the conventional technologies currently in use.

Vision for Improved Cancer Care

Dr. Lawrence Fong, who leads the collaboration for Fred Hutch, expressed optimism about the potential impact of this project. He emphasized that by better understanding the cellular and molecular responses to cancer therapies, the research could inform crucial treatment decisions for cancer patients. As the scientific director at the Integrated Immunotherapy Research Center, his experience with patients dealing with prostate, bladder, and kidney cancers strengthens the collaboration’s relevance.

Moreover, Serge Saxonov, the co-founder and CEO of 10x Genomics, highlighted that despite having access to more effective therapeutic options, there remains a gap in understanding which patients stand to gain the most benefit from such treatments. The application of single cell and spatial biology is posited as the key to unlocking insights into the biological underpinnings of treatment responses, thus laying the groundwork for precision oncology.

The partnership builds upon previous collaborations established by 10x Genomics with leading hospitals and research institutes, while also facilitating the establishment of a CLIA-certified laboratory for potential future diagnostic applications in oncology and autoimmune diseases. Together, 10x and Fred Hutch aim to construct a practical framework for clinical reporting, which will allow healthcare providers to utilize single cell and spatial features in devising effective treatment plans for patients afflicted with cancer.

About 10x Genomics

Founded to accelerate the mastery of biology and advance human health, 10x Genomics develops integrated research solutions encompassing instruments, consumables, and software tailored for single cell and spatial biology. Their technology aids researchers and biopharmaceutical companies in dissecting complex biological systems, ultimately driving breakthroughs in sectors like oncology, immunology, and neuroscience that reforge our comprehension of health and disease. To find out more about their ongoing innovations, visit 10xgenomics.com and connect on social media platforms such as LinkedIn, X, Facebook, Bluesky, and YouTube.

• ---

This article showcases the dynamic developments in cancer research made possible by 10x Genomics and Fred Hutch, exemplifying a commitment to improving patient care through innovative scientific advancements.